Stay updated on Efficacy of Rifaximin with NAC in IBS-D Clinical Trial
Sign up to get notified when there's something new on the Efficacy of Rifaximin with NAC in IBS-D Clinical Trial page.

Latest updates to the Efficacy of Rifaximin with NAC in IBS-D Clinical Trial page
- Check2 days agoChange DetectedA new Locations section has been added, listing California as a study site (Los Angeles, CA). The page's references to California Locations and the HHS Vulnerability Disclosure link were removed in revision 3.3.3.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe Publications section now states that entries are automatically filled from PubMed and may not all pertain to the study. The revision tag was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check38 days agoChange DetectedThe government funding status notice was removed from the page. The study details content and layout remain unchanged.SummaryDifference0.3%

- Check52 days agoChange DetectedNo significant changes detected; the study record details, including title, design, eligibility criteria, interventions, outcomes, and locations, appear unchanged between the screenshots.SummaryDifference0.4%

- Check81 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference2%

- Check88 days agoChange DetectedPage updated to Revision: v3.1.0; several MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) were removed.SummaryDifference0.3%

Stay in the know with updates to Efficacy of Rifaximin with NAC in IBS-D Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of Rifaximin with NAC in IBS-D Clinical Trial page.